Holen Sie sich die Stockscreener-App
2.61
12.07%
0.29
Schlusskurs vom Vortag:
$2.32
Offen:
$2.73
24-Stunden-Volumen:
333.99K
Relative Volume:
2.23
Marktkapitalisierung:
$97.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.27M
KGV:
-15.91
EPS:
-0.164
Netto-Cashflow:
$-7.70M
1W Leistung:
+16.59%
1M Leistung:
+31.98%
6M Leistung:
-10.96%
1J Leistung:
+102.33%
1-Tages-Spanne:
$2.4901
$2.77
1-Wochen-Bereich:
$2.05
$2.77
52-Wochen-Spanne:
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OKYO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.605 | 87.26M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-08 | Eingeleitet | B. Riley Securities | Buy |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
Dividend Watch: Will OKYO Pharma Limited stock benefit from green energy trendsMarket Volume Report & Daily Profit Maximizing Tips - ulpravda.ru
Will OKYO Pharma Limited stock benefit from green energy trendsQuarterly Earnings Summary & Weekly Hot Stock Watchlists - ulpravda.ru
Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 Patterns & Real-Time Buy Signal Alerts - ulpravda.ru
Will OKYO Pharma Limited stock outperform growth indexesStop Loss & Detailed Earnings Play Strategies - ulpravda.ru
Will OKYO Pharma Limited stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - ulpravda.ru
Will OKYO Pharma Limited stock recover faster than marketJuly 2025 WrapUp & Smart Money Movement Tracker - ulpravda.ru
Can OKYO Pharma Limited stock resist market sell offsQuarterly Earnings Summary & Fast Entry Momentum Alerts - ulpravda.ru
Entry Recap: Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 PostEarnings & Fast Gain Swing Trade Alerts - ulpravda.ru
What Wall Street predicts for OKYO Pharma Limited stock priceQuarterly Trade Review & Weekly Top Stock Performers List - ulpravda.ru
Is OKYO Pharma Limited stock trading at a premium valuationTechnical Pattern Recognition & Identify Winning Stocks - ulpravda.ru
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com
OKYO Pharma appoints Robert Dempsey as new CEO By Investing.com - Investing.com Nigeria
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential - TipRanks
OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO - Proactive financial news
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO - Proactive financial news
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - BioSpace
OKYO Pharma names Robert J. Dempsey as chief executive officer By Investing.com - Investing.com Australia
OKYO Pharma names Robert J. Dempsey as chief executive officer - Investing.com
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase - TipRanks
OKYO Pharma names ophthalmology veteran Robert J Dempsey as CEO to drive next growth phase - MSN
Is Alico Inc stock a smart buy before Fed meetingRisk Management & Fast Exit and Entry Trade Guides - moha.gov.vn
Will OKYO Pharma Limited stock remain a Wall Street favoriteTrendline Breakouts & Free High Yield Portfolio Picks - bollywoodhelpline.com
Technical Analysis: What dividend safety score for OKYO Pharma Limited stockMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
OKYO Pharma reports positive phase 2 results for Urcosimod in neuropathic corneal pain - MSN
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
Will OKYO Pharma Limited stock maintain dividend yieldJuly 2025 Catalysts & Trade Opportunity Analysis Reports - Улправда
Volatility Watch: How OKYO Pharma Limited OK11 stock gains from tech spendingJuly 2025 Price Swings & Verified High Yield Trade Plans - moha.gov.vn
Bank Watch: What Wall Street predicts for OKYO Pharma Limited stock priceJuly 2025 Levels & Daily Chart Pattern Signals - Улправда
Will OKYO Pharma Limited (OK11) stock hit analyst forecastsMarket Trend Review & Weekly High Return Stock Opportunities - Улправда
Is OKYO Pharma Limited stock affected by interest rate hikesTake Profit & AI Powered Market Trend Analysis - Улправда
Will OKYO Pharma Limited stock see PE expansionJuly 2025 Reactions & Stock Market Timing Techniques - Улправда
Small cap wrap: Gunnison Copper, OKYO Pharma, Abacus Global Management… - Proactive Investors
Is OKYO Pharma Limited (OK11) stock suitable for passive index fundsJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - Улправда
OKYO Pharma management to ring Nasdaq opening bell in New York - Investing.com Australia
Pullback Watch: Why retail investors pile into OKYO Pharma Limited stock2025 Market WrapUp & AI Driven Stock Movement Reports - DonanımHaber
OKYO Pharma Ltd Rings the Nasdaq Stock Market Opening Bell - Nasdaq
OKYO Pharma Ltd Rings the Opening Bell - Nasdaq
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors
OKYO Pharma management to ring Nasdaq opening bell in New York By Investing.com - Investing.com South Africa
OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data - TipRanks
OKYO Pharma to Ring the Opening Bell at Nasdaq - The Manila Times
How OKYO Pharma Limited (OK11) stock gains from tech spendingMarket Performance Summary & Expert Verified Stock Movement Alerts - DonanımHaber
Why OKYO Pharma Limited stock is rated strong buy2025 Growth vs Value & Comprehensive Market Scan Insights - DonanımHaber
Will OKYO Pharma Limited stock deliver long term returnsBreakout Watch & High Conviction Investment Ideas - Улправда
Is OKYO Pharma Limited stock positioned for digital transformation2025 Retail Activity & Precise Swing Trade Alerts - Улправда
OKYO Pharma reports favorable phase 2 data for NCP asset - Eyes On Eyecare
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):